With regard to immunosuppressant therapy at discharge, cancer groups used less T-cell-depleting antibodies (29.6%–31.4% vs. 28.3%) and mTOR inhibitors (5.2%–6.1% vs. 7.7%), but more tacrolimus (72.7%–74.9% vs. 71.8%) and mycophenolic acid (MPA; 84.3%–84.9% vs.81.9%) (Table 1). The gene discussed is MTOR; the disease is cancer.